Skip to main content
. 2016 Aug 23;7(38):62439–62459. doi: 10.18632/oncotarget.11516

Figure 2. Mass spectrometric analysis of synthetic CXCL12 and [3-NT7]CXCL12.

Figure 2

Chemically synthetized human CXCL12 and [3-NT7]CXCL12 were deprotected, folded and subsequently purified using RP-HPLC. Fractions were selected based on purity and correct relative molecular mass (Mr). Shown are the averaged mass spectrum of the final pool of synthetic purified and folded CXCL12 (panel A) and [3-NT7]CXCL12 (panel B) with the number of charges for the detected ions, ion intensities and corresponding mass to charge ratios (m/z) for the multiply charged ions. The inserts in panels A and B show the deconvoluted mass spectra with the Mr of the uncharged proteins calculated using the Bruker deconvolution software.